Phaseline

Targets › MAGEA3

MAGEA3 (Melanoma-associated antigen 3): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 4 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. (UniProt, P43357)

Open in Phaseline: the race on MAGEA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OSE ImmunotherapeuticsOSE2101
peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an
TP53, ERBB2, CEA, MAGEA2, MAGEA3Phase 3Patients With Non-Small Cell Lung Cancer; Solid Advanced TumorDec 2027
Canadian Cancer Trials GroupMG1MA3 (MG1 Maraba/MAGE-A3)
Replication-deficient adenovirus vaccine encoding MAGE-A3 tumor antigen
MAGEA3Phase 1Advanced/Metastatic Solid TumoursDec 2026
PDC*line Pharma SASPDC*lung01
Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1,
PRAME, MAGEA3, MAGEA4Phase 1Non Small Cell Lung Cancer–

Conditions

Advanced/Metastatic Solid Tumours (2) Patients With Non-Small Cell Lung Cancer (1) Solid Advanced Tumor (1) Non Small Cell Lung Cancer (1)

Modalities

protein or peptide (1), small molecule (1), mixed (1)

Companies

Canadian Cancer Trials Group (1) OSE Immunotherapeutics (1) PDC*line Pharma SAS (1)

Related targets

TP53 (1) ERBB2 (1) CEA (1) MAGEA2 (1) PRAME (1) MAGEA4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.